EDP-938 for Respiratory Syncytial Virus (RSV)

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Respiratory Syncytial Virus (RSV)EDP-938 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug to see if it can help people with RSV who are at high risk for complications.

Eligible Conditions
  • Respiratory Syncytial Virus (RSV)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 18 Secondary · Reporting Duration: Days 3, 5, 9, and 14

Day 33
Perinatal death
Change from Baseline for Health-Related Quality of Life
Change from Baseline for impact scale
Change from Baseline in severity of RSV LRTD symptoms
Duration of hospitalization for RSV or other causes
Percentage of participants with post-baseline RSV-related complications
Percentage of subjects requiring hospitalization for RSV or other causes;
Time to improvement in RSV disease
Time to no or mild impact of RSV disease on daily activities, emotions, and social relationships
Time to resolution of LRTD symptoms and 2 systemic symptoms
Respiratory Tract Diseases
Respiratory Tract Diseases
Respiratory syncytial virus
Time to return to usual activities
Time to return to usual health
Day 3
RSV RNA viral load change from Baseline
Up to Day 14
Change in infectious RSV viral load over time
Up to Day 33
Safety as measured by frequency of adverse events (AEs)
Up to Day 5
Pyruvate Kinase

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

EDP-938
1 of 2
Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

180 Total Participants · 2 Treatment Groups

Primary Treatment: EDP-938 · Has Placebo Group · Phase 2

EDP-938
Drug
Experimental Group · 1 Intervention: EDP-938 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
EDP-938
2021
Completed Phase 2
~420

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: days 3, 5, 9, and 14

Who is running the clinical trial?

Enanta Pharmaceuticals, IncLead Sponsor
38 Previous Clinical Trials
3,119 Total Patients Enrolled
3 Trials studying Respiratory Syncytial Virus (RSV)
180 Patients Enrolled for Respiratory Syncytial Virus (RSV)

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have congestive heart failure (CHF).
You are a woman of childbearing potential who is sexually active with a male
You are a male and you have not had a vasectomy and you are sexually active with a woman of childbearing potential